Avammune Therapeutics, Inc.
Avammune Therapeutics is a small molecule drug discovery and development company focused on developing modulators of the innate immune system for treating cancer. Their approach combines novel target biology, immunology, computational chemistry, and high-throughput chemistry to identify new targets and create a proprietary pipeline of small-molecule drug candidates for oncology.
Industries
Nr. of Employees
small (1-50)
Avammune Therapeutics, Inc.
Philadelphia, Pennsylvania, United States, North America
Products
Preclinical ENPP1 inhibitor (oral small-molecule; IND-enabling)
An orally available small-molecule ENPP1 inhibitor developed to activate the STING pathway and reduce tumor metastasis; demonstrated preclinical antitumor efficacy alone and in combination with checkpoint inhibitors, PARP inhibitors, chemotherapy and radiation; positioned for IND-enabling studies.
Preclinical ADAR1 p150-selective inhibitor (small-molecule)
A first-in-class small-molecule inhibitor selective for the p150 isoform of ADAR1 that induces interferon responses in vitro and shows antitumor activity in syngeneic melanoma models, including synergistic effects with checkpoint blockade.
Preclinical ENPP1 inhibitor (oral small-molecule; IND-enabling)
An orally available small-molecule ENPP1 inhibitor developed to activate the STING pathway and reduce tumor metastasis; demonstrated preclinical antitumor efficacy alone and in combination with checkpoint inhibitors, PARP inhibitors, chemotherapy and radiation; positioned for IND-enabling studies.
Preclinical ADAR1 p150-selective inhibitor (small-molecule)
A first-in-class small-molecule inhibitor selective for the p150 isoform of ADAR1 that induces interferon responses in vitro and shows antitumor activity in syngeneic melanoma models, including synergistic effects with checkpoint blockade.
Expertise Areas
- Small-molecule drug discovery
- Innate immunity modulation
- Immuno-oncology
- Medicinal chemistry and organic synthesis
Key Technologies
- Computational chemistry
- Parallel / high-throughput synthesis
- Small-molecule medicinal chemistry
- In vivo syngeneic tumor models